Ophthalmic Solution Articles & Analysis
3 news found
The 154-subject, multi-center, randomized, double-blind Phase 2b trial was designed to evaluate a single administration of one of twoiDose TRmodels with different travoprost release rates compared to topical timolol ophthalmic solution, 0.5% BID (twice a day). The primary efficacy endpoint agreed on with the U.S. ...
Food and Drug Administration (FDA) for the iPRIME™ Viscodelivery System, a sterile, single-use, minimally-invasive device for the delivery of viscoelastic fluid during ophthalmic surgery. “Since the introduction of our first iStent® Trabecular Micro-Bypass Stent in 2012, Glaukos has pioneered the MIGS marketplace and led a transformation in the way ...
Ivantis Inc., developer of the novel Hydrus® Microstent, a minimally invasive glaucoma surgery (MIGS) device designed to lower eye pressure in patients with open-angle glaucoma, is proud to be the recipient of multiple awards and recognition this year for its innovation and excellence in helping to change the standard of care for the world’s 80 million glaucoma patients, as well as its ...